Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/81—Protease inhibitors
  • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
  • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
  • G01N2333/8121—Serpins
  • G01N2333/8132—Plasminogen activator inhibitors
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
  • G01N2333/968—Plasmin, i.e. fibrinolysin
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
  • G01N2333/972—Plasminogen activators
  • G01N2333/9726—Tissue plasminogen activator

Definitions

• the present invention relates to an improved method for measuring tissue plasminogen activator, and plasminogen activator inhibitor, and soluble fibrin. More particularly, the present invention relates to a method for measuring plasminogen activator inhibitor and soluble fibrin which utilizes a genetically modified tissue plasminogen activator protein as a reagent. T'he present invention also relates to improved methods of collecting blood so that endogenous plasminogen activator is not inactivated.
• t-PA means "tissue plasminogen activator”.
• PAI means plasminogen activator inhibitor.
• PAI 1 is plasminogen activator inhibitor one and is sometimes called endothelial plasminogen activator inhibitor.
• PAI 2 is plasminogen activator inhibitor two and is sometimes called placental plasminogen activator inhibitor.
• 0C2AP means alpha 2 antiplasmin and is a protein found in blood of normal individuals that inhibits the enzyme plasmin.
• fibrinogen digests includes the products from digestion of fibrinogen or fibrin with proteolytic enzymes or plasmin. Investigation of tissue plasminogen activator inactivation in plasma has been hampered by poor methodology. A specific and sensitive method for measuring t-PA in plasma samples where potential fibrinolytic inhibitors were neutralized by controlled acidification was described. (See Wiman, B., et al., Clin.
• the t-PA inhibitory content was also determined in plasma from various patients. High inhibitory activity content was frequently found in patients with deep venous thrombosis, hemostatic problems during late pregnancy, or severe coronary heart disease. (See Chmielewska, J., et al., Thromb. Res.
• tPA activity is not stable in blood or in blood plasma and hence cannot be determined accurately be determined in regular citrated plasma samples. What is needed is a method of stabilizing the activity of tPA so that a sample of blood can be collected and analyzed under normal procedures. When prior art methods of collecting blood are used, much of the tPA activity is lost before the blood can be analyzed.
• PAI 1 activity will exert its biological activity on the assay system. What is needed is a method of inhibiting PAI 1 activity in the assay system when measuring t-PA activity in biological fluids.
• variants of one-chain t-PA where the -Arg- amino acid was replaced by a His (Arg to His) or by a Lys (Arg to Lys) or by a Thr (Arg to Thr) were made through genetic modification of the native t-PA protein.
• All the mutants including the uncleavable Arg to Thr mutant could be used in determination of PAI activity in plasma samples.
• the Arg to Thr mutant represents an advantage in PAI 1 activity determination. Preparations of the Arg to Thr mutant are sure to be free of two chain t-PA.
• the two chain t-PA in contrast to single chain t-PA, reacts readily with a second form of PAI known as PAI 2.
• PAI 2 a second form of PAI
• the present invention encompasses an improved method of collecting blood so that the t-PA present in the blood is stabilized and is not readily inactivated by PAI present in the blood.
• the improved method of collecting blood comprises acidifying the blood from the physiological pH of about 7.3 to a pH of between approximately 4.0 to 6.0.
• the preferred method of acidifying the blood for assaying t-PA is with citrate buffer although it is to be understood that other buffers can be used in practicing the present invention.
• Pluronic® F-68 to the blood citrate buffer mixture.
• Another aspect of the present invention is the discovery that fibrinogen is the plasma component that must be present for activation of t-PA by polylysine.
• Plasmin digests of fibrinogen or fibrin will also activate t-PA in the presence of polylysine.
• fibrinogen or fibrinogen digestion products
• Another object of the present invention is to provide a method of immediately lowering the pH of the blood with a minimum of hemolysis. It is yet another object of the present invention to provide a method of using polylysine in combination with fibrinogen or fibrinogen digests as a t-PA cofactor in non-blood biological fluids.
• Yet another object of the present invention is to provide an improved method of measuring fibrin in a sample utilizing a single chain t-PA that is resistant to cleavage by proteolytic enzymes.
• Another object of the present invention is to improve the assay of t-PA activity by including antibodies that inhibit PAI 1 and CC2 antiplasmin activities since these activities interfere with the assay of t-PA activity.
• Fig. 1 shows tPA activity in blood collected in different buffers.
• Native one-chain t-PA is cleaved by plasmin or by trypsin after the Arg in the sequence -Gln-Phe-Arg- ⁇ e-Lys- in the t-PA protein.
• t-PA activity is known to be stimulated by by fibrin or fibrin fragments.
• the stimulation of single chain t-PA by the presence of fibrin is much greater than that of the two chain t-PA.
• the mutant t-PA reacted poorly with polyclonal antibodies raised against the peptide -Gln-Pro-Gln-Phe-Arg-Ile-
• the specific activity expressed in IU/ ⁇ g were as follows: 810 (Arg to His), 640 (Arg to Lys), 290 (Arg to Thr) as compared to 810 for the wild type and 660 for Bowes melanoma t-PA.
• the amidolytic activity against D- ⁇ e-Pro-Arg-pNA at 37°C, pH 9.0 expressed in mOD per minute at l ⁇ g/ml of enzyme was 15.8 (Arg to His), 13.6
• t-PA's including the uncleavable Arg to Thr mutant could be used in determination of PAI activity in plasma samples.
• the Arg to Thr mutant represents a theoretical advantage in PAI 1 activity determination.
• Preparations of the Arg to Thr mutant are sure to be free of two chain t-PA which, in contrast to the single chain t-PA, also reacts readily with PAI 2. It is to be understood that the genetically modified t-
• PA that is described herein are readily made by those of ordinary skill in the recombinant DNA art.
• the plasminogen activation rate in the presence and absence of fibrin at 0.5 ⁇ m plasminogen and 37°C was measured and the stimulation factor calculated. This was about 950 fold for the Arg to Thr mutant which was considerably higher than that of melanoma one chain t-PA and the other mutant t-PA which were all about 550 fold.
• the stimulation factor for melanoma two chain t- PA was about 120 fold. It is to be understood that the extra fibrin sensitivity of the Arg to Thr mutant resulted in an improved soluble fibrin assay according to the Wiman-Ranby protocol (See Wiman, B and Rariby, M, Thromb. Haemostas. 55, 189-183 (1986)).
• the plasmin insensitive protein-engineered mutant t-PA is shown to be advantageous over prior art methods when used in assays for PAI 1 activity and soluble fibrin. It is to be understood mat the t-PA activity measured according to the present invention can optionally be determined using a reagent containing antibodies that inhibit anti-plasmin activity and PAI activity present in the biological fluid to be analyzed.
• the present invention also includes a method for determining the content of soluble fibrin in a sample comprising the steps of mixing a fixed amount of sample with a fixed amount of reagent containing one-chain t-PA, plasminogen and a plasmin substrate, measuring plasmin substrate cleavage correlating this rate with the amount of soluble fibrin in the sample.
• nine parts of blood is drawn into a container that contains one part citrate buffer with a pH of about 4 and a molarity of about 1 mol/1 of citrate.
• the final pH of the blood sample should preferably be between approximately 4.5 to 6.5.
• the citrate buffer should preferably be between 0.5 to 2 mol/1 of a sodium citrate buffer at a pH of approximately 4.0 to 5.5 to which 5 to 15 parts by volume of blood is added during collection.
• Pluronic® F-68 BASF Corporation, Parsippany, NJ
• the optimal final concentration of Pluronic® F-68 is between approximately 0.01% to 0.1% (0.1 to 1 mg/ml). It is to be understood that other Pluronic® surfactants can be used in the present invention to prevent hemolysis.
• the Pluronic® F-68 is a species within the following general formula:
• (C3H6O) has a molecular weight of approximately 950 to 4000, preferably about 1750 to 3500, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 50% to 90% by weight of the compound.
• Pluronic® F-68 has the following specific formula:
• the advantages of the procedure are that the rates of the reactions between t-PA and PAI 1 and between t-PA and other inhibitors of blood are reduced at a pH of about 5 as compared to those at the physiological pH of about 7.3. These reduced reaction rates will greatly increase the stability of t-PA activity in plasma.
• the present invention will improve the value of measuring t- PA activity to diagnose the etiology of thrombotic disease, the risk of developing thrombotic disease or the t-PA activity obtained during t-PA therapy.
• the preferred method of collecting blood for measuring tPA activity comprises collecting the blood in a container containing a citrate buffer.
• the buffer comprises approximately
• citrate buffer can have another metal cation such as potassium. Only moderate pH reduction is required to conserve tPA activity in the blood. Good tPA stability is found at a final pH range of approximately 5.3 to 5.8 with a preferred pH of approximately 5.5. These conditions are mild indicating that this approach may prove valuable for ther analytes, e.g., fibrinogen, plasminogen, ATIII, protein C, etc.
• the stability of PAI activity is increased significantly in blood samples collected according to the present invention as compared to those collected in a conventional way. This is of importance for this type of assay since the instability of PAI 1 activity is limiting the spread of this clinically important assay.
• the method according to the present invention preserves soluble fibrin levels in blood and plasma samples thereby improving the diagnostic importance of this important assay. High levels of soluble fibrin are found in the blood of patients with malignancies, risk pregnancies and in patients suffering from severe trauma. High levels of soluble fibrin is also a symptom of disseminated intravascular coagulation.
• the present invention of lowering the pH of blood during collection greatly improves the stability in the blood sample and in the plasma sample derived thereof of several important fibrinolytic parameters namely t-PA activity, PAI 1 activity and soluble fibrin.
• Pluronic® F-68 was obtained from BASF Corporation, Parsipanny, New Jersey. Blood was obtained by vein puncture and collected on 0.13 mol ⁇ trisodium c rate (1 part citrate buffer to 9 parts blood) in a siliconized Venoject® collection tube.
• 0.5 mol/l solutions of citric acid and of tri-sodium citrate were mixed to give 0.5 molA sodium citrate solutions with pH of 4.0, 4.5, 5.0 and 5.5. Each of these solutions was ahquoted and 25% F68 was added to give final concentrations of 0, 0.1 or 1% by weight.
• Citrated blood was dispensed in 300 ⁇ l aliquoted to which 33 ⁇ l of each of the 36 different buffers were added, mixed and incubated at room temperature (22°C) for 20 hours.
• the samples were centrifuged six minutes at 1500 x g, diluted six fold in 0.15 mol/l NaCl all and subjected to pH and absorptivity at 537 nm determination.
• the absorption value (optical density at 1 cm path length) was multiplied by the dilution factor of 6.
• Venoject® Teruno Europe, Lewen, Belgium, are evacuated siliconized 4.5 ml tubes containing 0.45 ml 0.13 motyl sodium citrate and are, in the following, called "Venoject regular".
• Some "Venoject regular” were modified as an embodiment of the present invention.
• the citrate buffer in the "Venoject regular” tubes is removed by suction with a hypodermic needle and 0.45 ml 1.0 motyl citrate buffer pH 4.0 is introduced through the rubber stopper with a hypodermic needle, hi this way, the citrate buffer content is changed without disturbing the vacuum in the tube.
• the modified tubes are hereinafter called “Venoject modified” .
• PA are incubated at room temperature (22°C) and 1 ml aliquots are drawn after 0.25, 1, 2 and 3 hours. The aliquots are centrifuged six minutes at 1500 x g and 100 ⁇ l plasma is acidified by addition of 1Q0 ⁇ l motyl acetate buffer pH 3.9 and analyzed according to the protocol of Wiman, et al. Clin. Chem. Act. Ill: 279-288 (1983) using Spectrolyse/fibrin reagents from Biopool AB, Umea, Sweden. The results of the study are shown in Table 2.
• t-PA activity in blood plasma is measured after blood sample collection in "Venoject regular” and “Venoject modified” with and without addition of about 9 IU/ml t-PA at time zero. The blood was incubated at room temperature for 0.25, 1, 2 and 3 hours before separation of the blood cells. t-PA activity is expressed in IU/ml. Table 2
• t-PA was stable in Venoject modified tubes while t-PA activity in unmodified tubes decreased rapidly.
• 4.5 ml of blood is collected on 0.5 ml of (Na) citrate buffer in siliconized glass tubes from the, cubital vein of sitting individuals using minimal stasis.
• buffers citrate buffers ranging from 0-.13 to 0.8 mol/l, pH range from approximately 3 to 5.5
• blood from 5 individuals is collected.
• the blood is aliquoted, 3x1.5 ml, into capped polystyrene tubes, incubated at 22°C for 0.05, 1 and 4 days.
• Plasma is obtained by centrifugation for 10 minutes at 3000 x g, frozen and stored at - 20°C.
• tPA activity is determined with a fibrin stimulated chromogenic substrate assay (Biopool AB, Umea, Sweden).
• tPA activity half life (tl/2) is then determined.
• the pH is measured with a standard glass electrode.
• Relative degree of hemoloysis, hemolysis factor (HF), is determined as increase in absorbance at a wavelength of 540 as compared to collection on 0.13 motyl tri-sodium citrate.
• the preferred buffer composition was found to be approximately 0.5 motyl of citrate at a pH of approximately 4.0.
• Fig. 1 and Table 3 shows tPA activity in blood at 0.05, 1 and 4 days after collection on citrate buffer, 0.5 mol/l at pH 4.0, and conventional 0.13 motyl tri-sodium citrate buffer.
• the tPA in the 0.5 motyl buffer was much more stable than tPA in the conventional buffer.
• the final pH of the blood sample was approximately 5.5 as compared to 8.3 with the conventional 0.13 motyl tri-sodium citrate buffer.
• the mean tPA activity half life in blood at roome temperature was 17 days when collected on the 0.5 mol/l citrate buffer at a pH of 4.0.
• Table 4 shows hemolysis in the two buffer systems. As shown, the hemolysis in the preferred buffer composition is acceptable.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Wood Science & Technology (AREA)
• Urology & Nephrology (AREA)
• Zoology (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biotechnology (AREA)
• General Health & Medical Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Cell Biology (AREA)
• Neurosurgery (AREA)
• Biophysics (AREA)
• General Physics & Mathematics (AREA)
• Medicinal Chemistry (AREA)
• Food Science & Technology (AREA)
• Pathology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=22092923

Family Applications (2)

Family Applications Before (1)

Country Status (7)

Families Citing this family (9)

Citations (1)

Family Cites Families (2)

• 1988
  • 1988-07-05 AT AT93113125T patent/ATE185376T1/de not_active IP Right Cessation
  • 1988-07-05 EP EP93113125A patent/EP0576038B1/en not_active Expired - Lifetime
  • 1988-07-05 CA CA000571186A patent/CA1324748C/en not_active Expired - Fee Related
  • 1988-07-05 WO PCT/US1988/002277 patent/WO1989000005A1/en not_active Application Discontinuation
  • 1988-07-05 AU AU23146/88A patent/AU2314688A/en not_active Abandoned
  • 1988-07-05 JP JP63506985A patent/JP2710376B2/ja not_active Expired - Fee Related
  • 1988-07-05 EP EP19880908071 patent/EP0324027A4/en not_active Withdrawn
  • 1988-07-05 DE DE3856367T patent/DE3856367T2/de not_active Expired - Fee Related

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events